Cresco Labs Past Earnings Performance
Past criteria checks 0/6
Cresco Labs's earnings have been declining at an average annual rate of -16.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 21.8% per year.
Key information
-16.7%
Earnings growth rate
-4.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 21.8% |
| Return on equity | -15.3% |
| Net Margin | -9.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cresco Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 726 | -67 | 223 | 0 |
| 30 Jun 24 | 735 | -172 | 227 | 0 |
| 31 Mar 24 | 747 | -155 | 241 | 0 |
| 31 Dec 23 | 756 | -176 | 260 | 0 |
| 30 Sep 23 | 767 | -339 | 284 | 0 |
| 30 Jun 23 | 786 | -234 | 295 | 0 |
| 31 Mar 23 | 806 | -211 | 307 | 0 |
| 31 Dec 22 | 825 | -212 | 310 | 0 |
| 30 Sep 22 | 842 | -65 | 295 | 0 |
| 30 Jun 22 | 848 | -326 | 295 | 0 |
| 31 Mar 22 | 841 | -318 | 292 | 0 |
| 31 Dec 21 | 806 | -320 | 276 | 0 |
| 30 Sep 21 | 750 | -360 | 276 | 0 |
| 30 Jun 21 | 687 | -73 | 246 | 0 |
| 31 Mar 21 | 573 | -105 | 215 | 0 |
| 31 Dec 20 | 463 | -102 | 199 | 0 |
| 30 Sep 20 | 345 | -76 | 163 | 0 |
| 30 Jun 20 | 231 | -98 | 145 | 0 |
| 31 Mar 20 | 168 | -64 | 119 | 0 |
| 31 Dec 19 | 124 | -43 | 92 | 0 |
| 30 Sep 19 | 101 | -20 | 77 | 0 |
| 30 Jun 19 | 78 | -14 | 63 | 0 |
| 31 Mar 19 | 57 | -12 | 46 | 0 |
| 31 Dec 18 | 41 | -2 | 31 | 0 |
| 30 Sep 18 | 28 | 0 | 19 | 0 |
| 30 Jun 18 | 19 | 1 | 9 | 0 |
| 31 Mar 18 | 13 | 1 | 7 | 0 |
| 31 Dec 17 | 10 | -3 | 5 | 0 |
| 31 Dec 16 | 3 | -8 | 4 | 0 |
Quality Earnings: 6CQ is currently unprofitable.
Growing Profit Margin: 6CQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6CQ is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare 6CQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6CQ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 6CQ has a negative Return on Equity (-15.34%), as it is currently unprofitable.